Idarubicin Injection 5 mg/5 mL (3)

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

idarubicin hydrochloride, Quantity: 1 mg/mL

Verfügbar ab:

Pfizer (Perth) Pty Ltd

Darreichungsform:

Injection, intravenous infusion

Zusammensetzung:

Excipient Ingredients: glycerol; hydrochloric acid; water for injections

Verabreichungsweg:

Intravenous Infusion

Einheiten im Paket:

1 X 5 mL

Verschreibungstyp:

(S1) This Schedule is intentionally blank

Anwendungsgebiete:

SOUTH AFRICA: Acute non-lymphocytic leukaemia (ANLL), including acute myeloblastic leukaemia (AML) in adults, for remission induction as front-line therapy, or for remission induction in relapsed or refractory patients. ZAVEDOS, in combination with cytarabine, is indicated for the first remission induction-line treatment of previously untreated children with acute myeloid leukaemia (AML)

Produktbesonderheiten:

Visual Identification: Red-orange, clear, mobile solution; Container Type: Vial; Container Material: PP; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Berechtigungsstatus:

Listed (Export Only)

Berechtigungsdatum:

2023-02-17